ClinicalTrials.gg
Status unknownNCT03375580Updated Dec 19, 2017

Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD

An interventional study of TLC and metformin in Nonalcoholic Fatty Liver Disease, sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-12-19.

Sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
20th of 89
196 · median 112
Started
2017
with 6 others
No phase
31 of 142
6 open now
Registered
25th of 142
by date

Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 20th largest by planned enrollment of the 89 interventional ones that give a count, is one of 7 that started in 2017, is one of 31 with no phase, and was the 25th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement in NAFLD parameters and changes in intestinal functions.

Read the detailed description

This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement in NAFLD parameters and changes in intestinal functions. In this study, the investigators will (1)evaluate the relationship between the function of intestinal mucosal barrier, SIBO, and NAFLD;(2)assess the effects of Compound Zhenzhu Tiaozhi capsules on intrahepatic fat content, hepatic noninvasive score, liver biochemical parameters, blood lipid, and insulin resistance. To evaluate the therapeutic effects of Compound Zhenzhu Tiaozhi capsules on the treatment of NAFLD, and determine whether the risk stratification of atherosclerotic cardiovascular disease (ASCVD) and quality of life (using the 36-Item Short Form Health Survey [SF-36]) can be improved in NAFLD patients with Compound Zhenzhu Tiaozhi capsules;(3) compare the therapeutic effects of Compound Zhenzhu Tiaozhi capsules with conventional medications in the treatment of NAFLD, and to compare their efficacies in improving the risk stratification of ASCVD and quality of life, as assessed by the SF-36; (4) analyze the relationship of Compound Zhenzhu Tiaozhi capsules in improving NAFLD and parameters related to the function of the intestinal mucosal barrier and SIBO.

03

Conditions studied

  • Nonalcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

clinical diagnosis of simple steatosis or NASH 18 to 75 years old serum (ALT)≤2 times the

Exclusion criteria

Exclusion Criteria:

other chronic liver diseases serious complications in other organs malignant tumors

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Placebo comparator
    TLC group

    transform life custom (TLC) group

    Dietary Supplement: TLC

  • Active comparator
    TLC + metformin group

    transform life custom (TLC) combined with 0.5g metformin, PO tid

    Dietary Supplement: TLC · Drug: metformin

  • Experimental
    TLC + CZT capsules group

    transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid

    Dietary Supplement: TLC · Drug: Compound Zhenzhu Tiaozhi capsule

  • Active comparator
    TLC + simvastatin group

    transform life custom (TLC) combined with 20mg simvastatin, PO qn

    Dietary Supplement: TLC · Drug: Simvastatin

Interventions

  • Dietary supplementTLC

    transform life custom (TLC)

  • 0.5g metformin group,PO tid

  • DrugCompound Zhenzhu Tiaozhi capsule

    Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.

  • 20mg simvastatin, PO qn

06

What researchers measure

Primary outcomes

  1. Fat attenuation index

    The fat attenuation index will be used to assess the therapeutic efficacy. A normal fat attenuation index is defined as \< 240 db/m, mild is 240-264 db/m, moderate is 265-294 db/m, and severity is \> 295 db/m.We will detect the fat attenuation index at 6 months following treatment. Effective: fat attenuation index is reduced by a level or more (example: moderate to mild). Invalid: fails to meet the effective standard.

    Time frame: at 6 months following therapy

Secondary outcomes

  1. Serum triglyceride

    detecting the serum level of triglyceride

    Time frame: at 6 months following therapy

  2. Serum cholesterol

    detecting the serum level of cholesterol

    Time frame: at 6 months following therapy

  3. Serum lipoproteins

    including chylomicron (CM), very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).

    Time frame: at 6 months following therapy

  4. Hydrogen/methane breath testing

    breath testing for SIBO

    Time frame: at 6 months following therapy

  5. Quality of life

    The quality of life of the patients before and after treatment will be assessed using the 36-Item Short Form Health Survey and compared to assess the improvement.

    Time frame: at 6 months following therapy

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital of Guangdong Pharmaceutical University
    Guangzhou, Guangdong 510080, China
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2017; primary completion for Aug 2019, 19 months later.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 19 months is below that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2017
First posted
Dec 18, 2017
StartEst.
Dec 31, 2017
Primary completionEst.
Aug 30, 2019
CompletionEst.
Dec 31, 2019
Last update
Dec 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03375580
Lead sponsor
The First Affiliated Hospital of Guangdong Pharmaceutical University
Responsible party
He Xingxiang (Director of the Hospital, The First Affiliated Hospital of Guangdong Pharmaceutical University) — Principal investigator
First posted
Dec 18, 2017
Start date
Dec 31, 2017 (estimated)
Primary completion
Aug 30, 2019 (estimated)
Completion
Dec 31, 2019 (estimated)
Last update
Dec 19, 2017

Study contacts

Xingxiang He, Dr.
Contact
hexingxiangtongxun@126.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion